doc and iwfal:
I tread carefully in commenting on any discussion that you are involved in since both individually and collectively you know more about this than I do. I will point out, however, that the pivotal TAX327 trial was an event based trial (of a therapy already approved in breast cancer) where approval came relatively soon after the approved experimental arm and the control arm passed the median survival points in a relatively large trial. Recent long-term survival data for the TAX 327 data places 36 montn survival at 18.6% to 20% (depending on the analysis done) vs. the 11% for the control arm in 9901, which was initiated in asymptomatic AIPC, and 45% of the TAX327 patients were symptomatic. I am not arguing against the position that long term survival of the 9901 experimental arm in 9901 at 34% was better, but, IMHO, those 51 of 147 patients in 9901 and 9902a that received the combination of Provenge and Taxotere and had a median survival of 34 months according to Dr. Petrylak's analysis were an important element in that result.
